Identification of Genes Contributing to Cisplatin Resistance in Osteosarcoma Cells

Overview

Journal FEBS Open Bio

Specialty Biology

Date 2022 Nov 21

PMID 36408691

Authors

Mingzhong Xie

Haoping Dai

Qingwen Gu

Changming Xiao

Haozhong Wang

Yang Lei

Chunxiao Wu

Xuening Li

Birong Lin

Sen Li

Affiliations

Soon will be listed here.

Abstract

Osteosarcomas are prevalent in children and young adults and have a high recurrence rate. Cisplatin, doxorubicin, and methotrexate are common adjuvant chemotherapy drugs for treatment of osteosarcoma, but multidrug resistance is a growing problem. Therefore, understanding the molecular mechanisms of chemotherapy resistance in osteosarcoma cells is crucial for developing new therapeutic approaches and ultimately improving the prognosis of osteosarcoma patients. To identify genes associated with cisplatin resistance in osteosarcoma, we screened a large-scale mutant library generated by transfecting human osteosarcoma cells with a piggyBac (PB) transposon-based gene activation vector. Several candidate genes were identified by using Splinkerette-PCR paired with Next Generation Sequencing. We created a disease-free survival predictor model, which includes ZNF720, REEP3, CNNM2, and CGREF1, using TARGET (Therapeutically Applicable Research to Generate Effective Treatments) datasets. Additionally, the results of our enrichment analysis between the Four_genes_high group and Low_group suggested that these four genes may participate in cisplatin resistance in osteosarcoma through cross talk between various signaling pathways, especially the signaling pathway related to bone formation. These data may help guide future studies into chemotherapy for osteosarcoma.

Citing Articles

Osteosarcoma: A comprehensive review of model systems and experimental therapies.

Robbins G, Vue Y, Rahrmann E, Moriarity B Med Res Arch. 2025; 12(11).

PMID: 39916749 PMC: 11801376. DOI: 10.18103/mra.v12i11.6000.

CGREF1 modulates osteosarcoma proliferation by regulating the cell cycle through the Wnt/β-catenin signaling pathway.

Wei Z, Xia K, Liu W, Huang X, Wei Z, Guo W Mol Med. 2024; 30(1):260.

PMID: 39707194 PMC: 11661040. DOI: 10.1186/s10020-024-01038-9.

Multiple Myeloma Cells with Increased Proteasomal and ER Stress Are Hypersensitive to ATX-101, an Experimental Peptide Drug Targeting PCNA.

Olaisen C, Rost L, Sharma A, Sogaard C, Khong T, Berg S Cancers (Basel). 2024; 16(23).

PMID: 39682151 PMC: 11640687. DOI: 10.3390/cancers16233963.

A novel prognostic model based on pyroptosis signature in AML.

Zhang H, Zhu H, Sheng Y, Cheng Z, Peng H Heliyon. 2024; 10(17):e36624.

PMID: 39263179 PMC: 11387551. DOI: 10.1016/j.heliyon.2024.e36624.

REEP3 is a potential diagnostic and prognostic biomarker correlated with immune infiltration in pancreatic cancer.

Liu G, Tan X, Xu Z, Li J, Zhong G, Zhai J Sci Rep. 2024; 14(1):13834.

PMID: 38879709 PMC: 11180088. DOI: 10.1038/s41598-024-64720-2.

References

Almada A, Horwitz N, Price F, Gonzalez A, Ko M, Bolukbasi O . FOS licenses early events in stem cell activation driving skeletal muscle regeneration. Cell Rep. 2021; 34(4):108656. PMC: 9112118. DOI: 10.1016/j.celrep.2020.108656. View

Schlaitz A, Thompson J, Wong C, Yates 3rd J, Heald R . REEP3/4 ensure endoplasmic reticulum clearance from metaphase chromatin and proper nuclear envelope architecture. Dev Cell. 2013; 26(3):315-23. PMC: 3745822. DOI: 10.1016/j.devcel.2013.06.016. View

Pettitt S, Rehman F, Bajrami I, Brough R, Wallberg F, Kozarewa I . A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One. 2013; 8(4):e61520. PMC: 3636235. DOI: 10.1371/journal.pone.0061520. View

Tian H, Zhou T, Chen H, Li C, Jiang Z, Lao L . Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway. J Orthop Res. 2019; 37(7):1638-1648. DOI: 10.1002/jor.24244. View

Hamilton A, Huntley S, Tran-Gyamfi M, Baggott D, Gordon L, Stubbs L . Evolutionary expansion and divergence in the ZNF91 subfamily of primate-specific zinc finger genes. Genome Res. 2006; 16(5):584-94. PMC: 1457049. DOI: 10.1101/gr.4843906. View

Funato Y, Miki H . The emerging roles and therapeutic potential of cyclin M/CorC family of Mg transporters. J Pharmacol Sci. 2021; 148(1):14-18. DOI: 10.1016/j.jphs.2021.09.004. View

Yu S, Guo J, Sun Z, Lin C, Tao H, Zhang Q . BMP2-dependent gene regulatory network analysis reveals Klf4 as a novel transcription factor of osteoblast differentiation. Cell Death Dis. 2021; 12(2):197. PMC: 7895980. DOI: 10.1038/s41419-021-03480-7. View

Brass A, Dykxhoorn D, Benita Y, Yan N, Engelman A, Xavier R . Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008; 319(5865):921-6. DOI: 10.1126/science.1152725. View

Herrera-Solorio A, Peralta-Arrieta I, Armas Lopez L, Hernandez-Cigala N, Mendoza Milla C, Ortiz Quintero B . LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases. Mol Oncol. 2021; 15(4):1110-1129. PMC: 8024737. DOI: 10.1002/1878-0261.12875. View

10.

Collier L, Carlson C, Ravimohan S, Dupuy A, Largaespada D . Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005; 436(7048):272-6. DOI: 10.1038/nature03681. View

11.

Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, Rice S . PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science. 2010; 330(6007):1104-7. PMC: 3719098. DOI: 10.1126/science.1193004. View

12.

Wang Z, Tan M, Chen G, Li Z, Lu X . LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2. IUBMB Life. 2017; 69(11):867-876. DOI: 10.1002/iub.1681. View

13.

Nowick K, Stubbs L . Lineage-specific transcription factors and the evolution of gene regulatory networks. Brief Funct Genomics. 2010; 9(1):65-78. PMC: 3096533. DOI: 10.1093/bfgp/elp056. View

14.

Takahashi C, Kondo S, Sadaoka K, Ishizuka S, Noguchi K, Kato Y . Effect of TNIK upregulation on JQ1-resistant human colorectal cancer HCT116 cells. Biochem Biophys Res Commun. 2020; 530(1):230-234. DOI: 10.1016/j.bbrc.2020.06.136. View

15.

Li H, Han X, Yang S, Wang Y, Dong Y, Tang T . FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53. Oncogene. 2021; 40(15):2785-2802. DOI: 10.1038/s41388-021-01742-4. View

16.

Zhang L, Chen Y, Li F, Bao L, Liu W . Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. Front Immunol. 2019; 10:867. PMC: 6498972. DOI: 10.3389/fimmu.2019.00867. View

17.

Lee A, Ferdjallah A, Moore E, Kim D, Nath A, Greengard E . Long Non-Coding RNA as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma. Int J Mol Sci. 2021; 22(20). PMC: 8538287. DOI: 10.3390/ijms222011168. View

18.

Tan J, Liang H, Yang B, Zhu S, Wu G, Li L . Identification and Analysis of Three Hub Prognostic Genes Related to Osteosarcoma Metastasis. J Oncol. 2021; 2021:6646459. PMC: 7867449. DOI: 10.1155/2021/6646459. View

19.

Wang Y, Deng X, Yu C, Zhao G, Zhou J, Zhang G . Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts. J Exp Clin Cancer Res. 2018; 37(1):251. PMC: 6192127. DOI: 10.1186/s13046-018-0922-0. View

20.

Deng W, Wang L, Xiong Y, Li J, Wang Y, Shi T . The novel secretory protein CGREF1 inhibits the activation of AP-1 transcriptional activity and cell proliferation. Int J Biochem Cell Biol. 2015; 65:32-9. DOI: 10.1016/j.biocel.2015.05.019. View